#United States #New York #Securities Fraud #Lead Plaintiff #Skye Bioscience

Important Update for Skye Bioscience, Inc. Investors

Investors in Skye Bioscience, Inc. (NASDAQ: SKYE) are urged to take note of a significant event unfolding in the realm of class action lawsuits. Levi & Korsinsky, LLP, a reputable law firm specializing in securities litigation, has put out a notification regarding an ongoing class action against the company. This action centers on allegations of securities fraud that potentially impacted numerous investors over a specific timeframe.

Lawsuit Overview

The class action is designed to recover losses for investors who were affected by purportedly misleading statements made by Skye Bioscience between November 4, 2024, and October 3, 2025. The core allegations suggest that the company misrepresented critical information about its lead product candidate, nimacimab. According to claims filed in the complaint, defendants allegedly downplayed the ineffectiveness of nimacimab, overstating its prospects in clinical and regulatory venues. Such actions could have misled investors about the company's actual performance and prospects, leading to significant financial losses.

The Significance of the Deadline

As stated by Levi & Korsinsky, the lead plaintiff deadline for this case is set for January 16, 2026. It is significant for potential plaintiffs to understand that participation in this lawsuit does not mandate being a lead plaintiff. Investors who suffered losses during the relevant period can seek redress by filing a claim. Notably, participating in the lawsuit does not incur any out-of-pocket costs for class members, making it accessible for all affected investors.

What Affected Investors Should Do

Affected investors are encouraged to act promptly. If you believe you have suffered losses as a result of misleading information provided by Skye Bioscience, it may be prudent to consult with legal experts. You may reach out to Joseph E. Levi, Esq. directly through the provided email or phone number to explore your options. Additionally, investors can access a submission form through the secured link provided, allowing for a streamlined process to get involved in the class action.

Why Choose Levi & Korsinsky?

Levi & Korsinsky has established itself as a noteworthy name in the landscape of securities litigation. With over 20 years of experience, they have successfully secured substantial settlements for investors affected by corporate misconduct. The firm has a dedicated team of around 70 specialists, all focused on advocating for clients' rights in complex legal settings. Their reputation has made them prominent within the top-tier of U.S. securities litigation firms as per ISS Securities Class Action Services, highlighting their consistent performance and commitment to their clients.

In conclusion, if you are an investor in Skye Bioscience, it is crucial to be aware of the upcoming deadline and the potential for recovery through this class action lawsuit. Engaging with experienced legal counsel can be an essential step towards seeking justice and compensation for your investment losses. Ensure you are informed, prepared, and ready to act as the clock ticks down to the January deadline.